Document Type : Review Article


Jarallh German specialized clinic laboratory,Kuwait, Kuwait



A model system for precision medicine has been suggested using tumor organoids. Tumor organoids are unique for cancer research on a patient-by-patient basis because they are able to preserve properties of the original tumor. As a result, it is alluring to consider using tumor organoids to improve patient outcomes during clinical decision-making. Patient outcomes have a good correlation with tumor organoid responses to a variety of medicines in vitro. Before application in clinical cancer care can be considered, however, there are still significant obstacles to be overcome and large cohort prospective trials are desperately needed. Tumor organoids offer a lot of potential in preclinical research due to their unique traits and direct connection to patient data. Here, we have evaluated the most recent developments in the development and use of cancer organoids grown from patients for cancer biology research and customized treatment. We have concentrated on the potential of organoids as a platform for the discovery and creation of innovative targeted therapies for the most intractable malignancy, pancreatobiliary cancer.


1.Dowden, Helen, and Jamie Munro. “Trends in clinical success rates and therapeutic focus.” Nat. Rev. Drug Discov 18.7 (2019): 495-6.
2.Hwang, Thomas J., et al. “Failure of investigational drugs in late-stage clinical development and publication of trial results.” JAMA internal medicine 176.12 (2016): 1826-1833.
3.Lee, Hye Won, et al. “Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.” Genome medicine 12.1 (2020): 1-21.
4.Veninga, Vivien, and Emile E. Voest. “Tumor organoids: opportunities and challenges to guide precision medicine.” Cancer Cell 39.9 (2021): 1190-1201.
5.Cobain, Erin F., et al. “Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors.” JAMA oncology 7.4 (2021): 525-533.
6.Li, Hongyi, et al. “Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.” Signal transduction and targeted therapy 5.1 (2020): 1-23.
7.Shiihara, Masahiro, and Toru Furukawa. “Application of Patient-Derived Cancer Organoids to Personalized Medicine.” Journal of Personalized Medicine 12.5 (2022): 789.
8.Ben-David, Uri, et al. “Genetic and transcriptional evolution alters cancer cell line drug response.” Nature 560.7718 (2018): 325-330.
9.Ren, Ya, et al. “Developments and opportunities for 3D bioprinted organoids.” International Journal of Bioprinting 7.3 (2021).
10.Huch, Meritxell, and Bon-Kyoung Koo. “Modeling mouse and human development using organoid cultures.” Development 142.18 (2015): 3113-3125.
11.Schutgens, Frans, and Hans Clevers. “Human organoids: tools for understanding biology and treating diseases.” Annual Review of Pathology: Mechanisms of Disease 15 (2020): 211-234.
12.Wang, Qinying, et al. “Applications of human organoids in the personalized treatment for digestive diseases.” Signal Transduction and Targeted Therapy 7.1 (2022): 1-30.
13.Assawachananont, Juthaporn, et al. “Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice.” Stem cell reports 2.5 (2014): 662-674.
14.McCracken, Kyle W., et al. “Modelling human development and disease in pluripotent stem-cell-derived gastric organoids.” Nature 516.7531 (2014): 400-404.
15.Spence, Jason R., et al. “Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro.” Nature 470.7332 (2011): 105-109.
16.Chen, Kevin G., et al. “Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.” Drug discovery today 24.11 (2019): 2126-2138.
17.Nozaki, Kengo, et al. “Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes.” Journal of gastroenterology 51.3 (2016): 206-213.‏
18.Ben-David, Uri, et al. “Genetic and transcriptional evolution alters cancer cell line drug response.” Nature 560.7718 (2018): 325-330.
19.Ghajari, Ghazal, Arefe Heydari, and Masoud Ghorbani. “Mesenchymal stem cell-based therapy and female infertility: limitations and advances.” Current Stem Cell Research & Therapy (2022).
20.Ben-David, Uri, et al. “Patient-derived xenografts undergo mouse-specific tumor evolution.” Nature genetics 49.11 (2017): 1567-1575.
21.Broutier, Laura, et al. “Human primary liver cancer–derived organoid cultures for disease modeling and drug screening.” Nature medicine 23.12 (2017): 1424-1435.
22.Boj, Sylvia F., et al. “Organoid models of human and mouse ductal pancreatic cancer.” Cell 160.1-2 (2015): 324-338.
23.Broutier, Laura, et al. “Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation.” Nature protocols 11.9 (2016): 1724-1743.
24.Van de Wetering, Marc, et al. “Prospective derivation of a living organoid biobank of colorectal cancer patients.” Cell 161.4 (2015): 933-945.
25.Kim, Minsuh, et al. “Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.” Nature communications 10.1 (2019): 1-15.
26.Wong, Chi Heem, Kien Wei Siah, and Andrew W. Lo. “Estimation of clinical trial success rates and related parameters.” Biostatistics 20.2 (2019): 273-286.
27.Veninga, Vivien, and Emile E. Voest. “Tumor organoids: opportunities and challenges to guide precision medicine.” Cancer Cell 39.9 (2021): 1190-1201.
28.Kretzschmar, Kai. “Cancer research using organoid technology.” Journal of Molecular Medicine 99.4 (2021): 501-515.
29.Drost, Jarno, and Hans Clevers. “Organoids in cancer research.” Nature Reviews Cancer 18.7 (2018): 407-418.
30.Kodack, David P., et al. “Primary patient-derived cancer cells and their potential for personalized cancer patient care.” Cell reports 21.11 (2017): 3298-3309. Witte, Chris Jenske, et al. “Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter-and intrapatient drug responses.” Cell reports 31.11 (2020): 107762.
32.Ooft, S. N., et al. “Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.” ESMO open 6.3 (2021): 100103.
33.Huang, Ling, et al. “Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell–and patient-derived tumor organoids.” Nature medicine 21.11 (2015): 1364-1371.
34.Karthaus, Wouter R., et al. “Identification of multipotent luminal progenitor cells in human prostate organoid cultures.” Cell 159.1 (2014): 163-175.
35.Dijkstra, Krijn K., et al. “Patient-derived organoid models of human neuroendocrine carcinoma.” Frontiers in endocrinology 12 (2021): 627819.
36.Patel, Tushar. “Worldwide trends in mortality from biliary tract malignancies.” BMC cancer 2.1 (2002): 1-5.‏
37.Khan, Shahid A., et al. “Changing international trends in mortality rates for liver, biliary and pancreatic tumours.” Journal of hepatology 37.6 (2002): 806-813.
38.Carriaga, Marisa T., and Donald Earl Henson. “Liver, gallbladder, extrahepatic bile ducts, and pancreas.” Cancer 75.S1 (1995): 171-190.
39.Abou-Alfa, Ghassan K., et al. “Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.” The Lancet Oncology 21.6 (2020): 796-807.‏
40.Unno, Michiaki, Tatsuo Hata, and Fuyuhiko Motoi. “Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.” Surgery today 49.4 (2019): 295-299.
41.Biankin, Andrew V., et al. “Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.” Nature 491.7424 (2012): 399-405.
42.Dalton, W. Brian. DNA damage during mitotic arrest: A novel, p53-regulated source of structural chromosome instability in human cells. Diss. Emory University, 2008.
43.Shiihara, Masahiro, et al. “Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers.” European Journal of Cancer 148 (2021): 239-250.
44.Seino, Takashi, et al. “Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression.” Cell stem cell 22.3 (2018): 454-467.
45.Jusakul, Apinya, et al. “Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of CholangiocarcinomaIntegrative Genomic and Epigenomic Analysis of Cholangiocarcinoma.” Cancer discovery 7.10 (2017): 1116-1135.
46.Driehuis, Else, et al. “Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.” Proceedings of the National Academy of Sciences 116.52 (2019): 26580-26590.
47.Hu, Tuo, et al. “Metabolic rewiring by loss of Sirt5 promotes Kras-induced pancreatic cancer progression.” Gastroenterology 161.5 (2021): 1584-1600.
48.Fujiwara, Hiroaki, et al. “5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids.” Surgical Oncology 35 (2020): 484-490.
49.Tsai, Susan, et al. “Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.” BMC cancer 18.1 (2018): 1-13.
50.Koikawa, Kazuhiro, et al. “Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.” Cell 184.18 (2021): 4753-4771.
51.Öhlund, Daniel, et al. «Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.» Journal of Experimental Medicine 214.3 (2017): 579-596.
52.Grandori, Carla, and Christopher J. Kemp. “Personalized cancer models for target discovery and precision medicine.” Trends in cancer 4.9 (2018): 634-642.
53.Nussinov, Ruth, et al. “Precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers.” PLoS computational biology 15.3 (2019): e1006658.
54.Saito, Yoshimasa, et al. “Establishment of patient-derived organoids and drug screening for biliary tract carcinoma.” Cell reports 27.4 (2019): 1265-1276.
55.Pauli, Chantal, et al. “Personalized In Vitro and In Vivo Cancer Models to Guide Precision MedicinePersonalized Cancer Models to Guide Precision Medicine.” Cancer discovery 7.5 (2017): 462-477.
56.Larsen, Brian M., et al. “A pan-cancer organoid platform for precision medicine.” Cell reports 36.4 (2021): 109429.
57.Narasimhan, Vignesh, et al. “Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized TherapyFunctional Precision Medicine for Advanced Colorectal Cancer.” Clinical Cancer Research 26.14 (2020): 3662-3670.
58.Gilles, Maud-Emmanuelle, et al. “Personalized RNA medicine for pancreatic cancer.” Clinical Cancer Research 24.7 (2018): 1734-1747.
59.Tung, Kuei-Ling, et al. “Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistance.” Genes & diseases 8.2 (2021): 203-214.
60.Broutier, Laura, et al. “Human primary liver cancer–derived organoid cultures for disease modeling and drug screening.” Nature medicine 23.12 (2017): 1424-1435.
61.Neal, James T., et al. “Organoid modeling of the tumor immune microenvironment.” Cell 175.7 (2018): 1972-1988.
62.Schnalzger, Theresa E., et al. “3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids.” The EMBO journal 38.12 (2019): e100928.
63.Forsythe, Steven D., et al. “Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility StudyImmunotherapy Efficacy in Appendiceal Cancer Organoids.” Clinical Cancer Research 27.18 (2021): 5141-5150.
64.Votanopoulos, Konstantinos I., et al. “Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study.” Annals of surgical oncology 26.1 (2019): 139-147.
65.Nuciforo, Sandro, et al. “Organoid models of human liver cancers derived from tumor needle biopsies.” Cell reports 24.5 (2018): 1363-1376.
66.Pasch, Cheri A., et al. “Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation.” Clinical Cancer Research 25.17 (2019): 5376-5387.